Compounds > alanine
Page last updated: 2024-11-08

alanine and Lassitude

alanine has been researched along with Lassitude in 10 studies

Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.

Research Excerpts

ExcerptRelevanceReference
"Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)."9.16Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. ( Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I, 2012)
"20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo)."5.19Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. ( Alcindor, T; Au, HJ; Easaw, JC; El-Tahche, F; Jeffery, M; Jonker, DJ; Kotb, R; Moore, MJ; Ng, S; O'Callaghan, CJ; Ringash, J; Sabesan, S; Salim, M; Shannon, J; Shapiro, JD; Siu, LL; Strickland, A; Tu, D; Walters, I; Zalcberg, JR, 2014)
"Brivanib, a selective dual inhibitor of fibroblast growth factor and VEGF signaling, has recently been shown to have activity as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)."5.16Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. ( Baudelet, C; Finn, RS; Kang, YK; Lim, HY; Manekas, D; Mulcahy, M; Park, JW; Polite, BN; Walters, I, 2012)
"73 log10 copies per milliliter, including a dose-response relationship for viral load decrease up to 25 mg."2.78Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. ( Berger, D; Bredeek, UF; Callebaut, C; DeJesus, E; Fordyce, MW; Markowitz, M; Ramanathan, S; Rhee, MS; Ruane, PJ; Yale, K; Zhong, L, 2013)
"Time to fatigue was not different (P greater than 0."1.28Metabolic responses to ammonium acetate infusion in exercising horses. ( Bump, K; Fisher, M; Foreman, J; Kurcz, E; Lawrence, L; Miller-Graber, P, 1991)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's0 (0.00)29.6817
2010's5 (50.00)24.3611
2020's4 (40.00)2.80

Authors

AuthorsStudies
Kaye, AD1
Cornett, EM1
Brondeel, KC1
Lerner, ZI1
Knight, HE1
Erwin, A1
Charipova, K1
Gress, KL1
Urits, I1
Urman, RD1
Fox, CJ1
Kevil, CG1
Mayer, KH1
Gelman, M1
Holmes, J1
Kraft, J1
Melbourne, K1
Mimiaga, MJ1
De Masi, C1
Liguori, C1
Spanetta, M1
Fernandes, M1
Cerroni, R1
Garasto, E1
Pierantozzi, M1
Mercuri, NB1
Stefani, A1
Lu, L1
Zheng, X1
Wang, S1
Tang, C1
Zhang, Y1
Yao, G1
Zeng, J1
Ge, S1
Wen, H1
Xu, M1
Guyatt, G1
Xu, N1
Coqueiro, AY1
Raizel, R1
Bonvini, A1
Hypólito, T1
Godois, ADM1
Pereira, JRR1
Garcia, ABO1
Lara, RSB1
Rogero, MM1
Tirapegui, J1
Ruane, PJ1
DeJesus, E1
Berger, D1
Markowitz, M1
Bredeek, UF1
Callebaut, C1
Zhong, L1
Ramanathan, S1
Rhee, MS1
Fordyce, MW1
Yale, K1
Ringash, J1
Au, HJ1
Siu, LL1
Shapiro, JD1
Jonker, DJ1
Zalcberg, JR1
Moore, MJ1
Strickland, A1
Kotb, R1
Jeffery, M1
Alcindor, T1
Ng, S1
Salim, M1
Sabesan, S1
Easaw, JC1
Shannon, J1
El-Tahche, F1
Walters, I2
Tu, D1
O'Callaghan, CJ1
McCormack, WP1
Hoffman, JR1
Pruna, GJ1
Jajtner, AR1
Townsend, JR1
Stout, JR1
Fragala, MS1
Fukuda, DH1
Finn, RS1
Kang, YK1
Mulcahy, M1
Polite, BN1
Lim, HY1
Baudelet, C1
Manekas, D1
Park, JW1
Miller-Graber, P1
Lawrence, L1
Fisher, M1
Bump, K1
Foreman, J1
Kurcz, E1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1[NCT03499483]Phase 452 participants (Actual)Interventional2019-01-24Completed
Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.[NCT03126370]Phase 410 participants (Actual)Interventional2018-01-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Week 12 Plasma Tenofovir Area Under the Plasma Concentration vs. Time Curve From Time 0 to 24 Hours (AUC0-24) at 24 and 28 Weeks

Compare plasma tenofovir AUC0-24 between TAF with boosted PI vs. TDF with boosted PI (Phase 2 vs. 1), and between TAF with boosted PI and LDV/SOF vs. TDF with boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 weeks and 28 weeks

Interventionng*h/mL (Geometric Mean)
TDF With a Boosted PI3466
TAF With a Boosted PI743
TAF With a Boosted PI and LDV/SOF868

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Dried Blood Spots (DBS)

Compare tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1) (NCT03126370)
Timeframe: 12 weeks and 24 and 28 weeks

Interventionfmol/2x7mm punches (Geometric Mean)
TDF With a Boosted PI36014
TAF With a Boosted PI6735
TAF With a Boosted PI and LDV/SOF6100

Change From Week 12 Tenofovir-diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs) at 24 and 28 Weeks

Compare tenofovir-diphosphate (TFV-DP) in peripheral blood mononuclear cells (PBMCs) between TAF with a boosted PI vs. TDF with a boosted PI (Phase 2 vs. 1), and TAF with a boosted PI and LDV/SOF vs. TDF with a boosted PI (Phase 3 vs. 1). (NCT03126370)
Timeframe: 12 weeks, and 24 weeks and 28 weeks

Interventionfmol/10^6 cells (Geometric Mean)
TDF With a Boosted PI83.0
TAF With a Boosted PI926
TAF With a Boosted PI and LDV/SOF1129

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: eGFR

Change in estimated glomerular filtration rate (eGFR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

InterventionmL/min/1.73 m^2 (Geometric Mean)
TDF With a Boosted PI86.7
TAF With a Boosted PI91.0
TAF With a Boosted PI and LDV/SOF88.1

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: UPCR

Change in estimated glomerular filtration rate (eGFR) and renal biomarkers: Urine protein to creatinine ratio (UPCR) (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

Interventionmg/g (Geometric Mean)
TDF With a Boosted PI134
TAF With a Boosted PI118
TAF With a Boosted PI and LDV/SOF97.3

Change in Estimated Glomerular Filtration Rate (eGFR) and Renal Biomarkers: B2M/Cr Ratio, and RBP/Cr Ratio

Change in renal biomarkers: urinary beta-2 microglobulin (B2M)/creatinine (Cr) ratio, and urinary retinol binding protein (RBP)/Cr ratio (NCT03126370)
Timeframe: 12 weeks, 24 weeks, and 28 weeks

,,
Interventionug/g (Geometric Mean)
β2M:Cr ratioRBP:Cr ratio
TAF With a Boosted PI224242
TAF With a Boosted PI and LDV/SOF178146
TDF With a Boosted PI419436

Reviews

2 reviews available for alanine and Lassitude

ArticleYear
Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment.
    Best practice & research. Clinical anaesthesiology, 2021, Volume: 35, Issue:3

    Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Animals; Antiviral Agents; Coronavirus; C

2021
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
    Journal of neurology, neurosurgery, and psychiatry, 2020, Volume: 91, Issue:12

    Topics: Acitretin; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Anx

2020

Trials

3 trials available for alanine and Lassitude

ArticleYear
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
    Journal of acquired immune deficiency syndromes (1999), 2013, Aug-01, Volume: 63, Issue:4

    Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Area Under Curve; Dose-Response Relationship, Drug;

2013
Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial.
    Cancer, 2014, Jan-15, Volume: 120, Issue:2

    Topics: Alanine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuxima

2014
Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-01, Volume: 18, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alanine; alpha-Fetoproteins; Appetite; Carcino

2012

Other Studies

5 other studies available for alanine and Lassitude

ArticleYear
Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure.
    Journal of acquired immune deficiency syndromes (1999), 2022, 05-01, Volume: 90, Issue:1

    Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Emtricitabine; Fatigue; Female; Heterocyclic Compounds, 3

2022
Non-motor symptoms burden in motor-fluctuating patients with Parkinson's disease may be alleviated by safinamide: the VALE-SAFI study.
    Journal of neural transmission (Vienna, Austria : 1996), 2022, Volume: 129, Issue:11

    Topics: Alanine; Benzylamines; Fatigue; Female; Humans; Male; Pain; Parkinson Disease; Quality of Life

2022
Effects of Glutamine and Alanine Supplementation on Central Fatigue Markers in Rats Submitted to Resistance Training.
    Nutrients, 2018, Jan-25, Volume: 10, Issue:2

    Topics: Alanine; Ammonia; Animals; Blood Glucose; Dietary Supplements; Dipeptides; Dopamine; Fatigue; Fatty

2018
Effects of l-Alanyl-l-Glutamine Ingestion on One-Hour Run Performance.
    Journal of the American College of Nutrition, 2015, Volume: 34, Issue:6

    Topics: Adult; Alanine; Beverages; Blood Glucose; Dipeptides; Electrolytes; Exercise; Fatigue; Glutamine; Hu

2015
Metabolic responses to ammonium acetate infusion in exercising horses.
    The Cornell veterinarian, 1991, Volume: 81, Issue:4

    Topics: Acetates; Alanine; Ammonia; Animals; Blood Urea Nitrogen; Fatigue; Female; Glutamates; Glutamic Acid

1991